去纤苷对肝小静脉闭塞病有效吗？

Is defibrotide (sodium defibrotide) effective for hepatic veno-occlusive disease? Recently, many patients with hepatic veno-occlusive disease will ask this question. Let’s take a look at the effects of defibrinoside (defiteli). Defibrotide (sodium defibrotide) is an effective drug suitable for the treatment of hepatic veno-occlusive disease. It is a mixture of single-stranded oligonucleotides with anti-thrombotic and fibrinolytic effects. In recent years, the results of multiple clinical studies have shown that defibrotide (defibrotide sodium) is a safe and effective drug for preventing and treating HVOD after HSCT.

Defibrinoside (Defibrotide Sodium) was first developed by Gentium Pharmaceuticals in Italy and was approved for marketing in the EU in October 2013. After Gentium Pharmaceuticals was acquired by Jazz Pharmaceuticals of the United States, defibrotide (sodium defibrotide) was approved by the U.S. Food and Drug Administration (FDA) to be marketed in the United States on March 30, 2016, under the trade name Defitelio. 

Hepatic veno-occlusive disease (HVOD) is one of the serious complications after hematopoietic stem cell transplantation (HSCT), and the mortality rate in patients with severe HVOD can be as high as 100%. Defibrotide is a mixture of single-stranded oligonucleotides with antithrombotic and fibrinolytic effects. In recent years, the results of multiple clinical studies have shown that defibrotide (defibrotide sodium) is a safe and effective drug for preventing and treating HVOD after HSCT.

In clinical trials, heparin was used to prevent diseases such as hepatic venous occlusion while greatly increasing the risk of bleeding. However, defibrotide (defibrotide sodium) alone or in combination with heparin has a very low incidence of side effects and has achieved a good effect in preventing HV0D. In a phase III multi-center randomized clinical trial completed in Europe, a total of 356 stem cell transplant patients were recruited. The incidence of hepatic vein occlusion 30 days after transplantation was compared. It was found that 2 of 180 patients in the defibrotide (sodium defibrotide) group developed hepatic vein occlusion, accounting for 12%; 35 of 176 patients in the control group developed hepatic vein occlusion, accounting for 20%. Defibrinoside (Defibrotide Sodium) has a remarkable therapeutic effect and plays an indispensable role in the field of hepatic veno-occlusive disease.